Mersana Therapeutics Inc Stock Price, News & Analysis

Mersana Therapeutics (NASDAQ:MRSN) announced a conference call on November 9, 2021, at 8:00 a.m. ET to discuss third-quarter financial results ending September 30, 2021. The clinical-stage biopharmaceutical company specializes in antibody-drug conjugates (ADCs) for cancer treatment and is developing several product candidates, including upifitamab rilsodotin (UpRi). UpRi targets NaPi2b and is under evaluation in multiple studies for ovarian cancer treatment. Investors can access the call via phone or webcast through the company’s website.

Mersana Therapeutics (Nasdaq: MRSN) has appointed Mohan Bala, Ph.D., as Senior Vice President of Strategic Product Planning & Program Leadership. To entice Dr. Bala, the Compensation Committee granted him a stock option for 112,500 shares at $8.63 per share, the closing price on the grant date. The options will vest over four years, with 25% vesting on the first anniversary of his start date and the remainder vesting quarterly. Mersana is focused on developing antibody-drug conjugates (ADCs) for cancer treatment, including their lead candidate UpRi for ovarian cancer.

Mersana Therapeutics has appointed Mohan Bala, Ph.D., as SVP, Strategic Product Planning & Program Leadership, effective October 25, 2021. He takes over responsibilities from Brian DeSchuytner, who has been named SVP and Chief Financial Officer. Dr. Bala brings over 20 years of experience in clinical development, having launched seven oncology products globally. This leadership change is expected to strengthen Mersana's efforts in advancing its clinical pipeline, especially UpRi, a candidate for treating ovarian cancer.

Mersana Therapeutics (NASDAQ:MRSN) has announced promising preclinical data for XMT-2056, its first Immunosynthen STING-agonist ADC candidate, targeting a novel epitope of HER2. Presented at the AACR-NCI-EORTC conference, data shows that XMT-2056 activates the STING pathway effectively in tumor cells and immune cells, outperforming trastuzumab-TLR7/8 agonist ADCs. The ADC demonstrates increased efficacy in various HER2 models and potential for combination treatments with existing HER2 therapies. The compound also shows excellent tolerability in NHP studies, suggesting a broad therapeutic index.

Mersana Therapeutics (NASDAQ:MRSN) announced its upcoming presentation of preclinical data for XMT-2056, its first STING-agonist ADC, at the AACR-NCI-EORTC Virtual Conference on Molecular Targets and Cancer Therapeutics. The session is scheduled for October 7, 2021, featuring Dr. Timothy B. Lowinger, the Chief Science & Technology Officer. This event highlights Mersana's innovations in antibody-drug conjugates aimed at targeting cancers with significant unmet medical needs, strengthening its pipeline that includes UpRi and XMT-1592.

Mersana Therapeutics (NASDAQ:MRSN), a clinical-stage biopharmaceutical company, announced management presentations at three investor conferences. The Baird 2021 Global Healthcare Conference will take place on September 14, 2021, at 8:30 a.m. ET, followed by the Morgan Stanley 19th Annual Global Healthcare Conference on September 15, 2021, at 1:15 p.m. ET. Lastly, the 2021 Cantor Virtual Global Healthcare Conference is set for September 28, 2021, at 4:00 p.m. ET. A live webcast will be accessible on Mersana's website, with an archived replay available for 90 days.

Mersana Therapeutics (NASDAQ:MRSN) has announced a live conference call and webcast on September 10, 2021, at 8:00 a.m. ET to discuss the development strategy of its ADC candidate, upifitamab rilsodotin (UpRi), and share updated interim data from the ovarian cancer expansion cohort of the Phase 1 study. The expansion cohort has completed enrollment with 97 patients evaluable for safety, of which 75 are RECIST-evaluable. Key executives, including lead investigator Debra L. Richardson, MD, will participate in the call.

Mersana Therapeutics (Nasdaq: MRSN) has announced the appointment of Tushar Misra, Ph.D., as Senior Vice President and Chief Manufacturing Officer, with a stock option grant of up to 112,500 shares priced at $11.56 each. This grant serves as an inducement for Dr. Misra's employment and vests over four years. Mersana specializes in antibody-drug conjugates (ADCs) for cancer treatment, with lead candidate upifitamab rilsodotin currently in clinical studies for ovarian cancer. The company aims to enhance efficacy and safety in treating cancer patients.

Mersana Therapeutics has appointed Tushar Misra, Ph.D., as its new Chief Manufacturing Officer, effective August 16, 2021. He takes over from Michael Kaufman, Ph.D., who will retire following a transition period ending on September 10, 2021. Misra brings extensive experience from his previous roles in major biopharmaceutical companies. His leadership is expected to advance the company’s clinical programs, particularly for UpRi, aimed at treating ovarian cancer.